Navigation Links
AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000
Date:1/25/2008

TUSTIN, Calif., Jan. 25 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company that, together with Jade, engages in the development, manufacture and marketing of proprietary pharmaceutical, health care and diagnostic products. It today announced that more than 100 individual owners of existing health spa centers in China have signed strategic cooperation agreements with JJB, a Jade subsidiary.

The agreements allow JJB to re-brand the locations as JPGreen anti-aging & spa clinics. JJB is the exclusive supplier of its anti-aging product "Goodnak." The agreements follow a January meeting at the Beijing Diaoyutai State Guesthouse that attracted approximately 200 health spa center owners who want to cooperate with JJB in order to expand the JPGreen centers.

Frank Zhang, Managing Director of Jade, stated that "these new strategic cooperation agreements will allow JJB to increase the sales of the expanding family of Goodnak anti-aging injections, capsules, creams and spray products into the China market during 2008. Each new clinic location is anticipated to annually contribute $400,000 to $700,000 in gross sales per location."

Mr. Gary Dreher, CEO of AMDL noted that "these new regional Chinese strategic cooperation relationships are significant achievements and improves Jade's ability to grow its sales in 2008 and beyond."

About Jade Pharmaceutical: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice ('CGMP') standards.

About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: AMDL, Inc.

Gary L. Dreher

President & CEO

(714) 505-4460


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
2. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
3. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
4. Monsanto Company Signs Share Subscription Agreement With Devgen
5. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
6. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
7. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
8. Assay Designs(TM) Announces Additions to the Leadership Team
9. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2017)... Maryland (PRWEB) , ... September ... ... proudly announces the launch of its CliniControl™ (CC) product portfolio, clinically-relevant starting ... accelerating clinical translation of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl ...
(Date:9/14/2017)... ... September 14, 2017 , ... AxioMed is pleased ... Australia. Dr. Steven Yang completed the procedure on a 35-year-old female patient suffering ... lumbar disc at level L5-S1. The patient failed conservative treatments prior to undergoing ...
(Date:9/14/2017)... ... September 14, 2017 , ... AIM Global, the worldwide standards agency for ... won the 2017 Case Study Competition for AIDC. The award is given to ... risk” and push the adoption of automated data collection systems further. The TRACTUS ...
(Date:9/13/2017)... (PRWEB) , ... September 13, 2017 , ... ... with the life sciences industry to improve patient outcomes and quality of life ... & impurities, has been named a US expert to the International Standards ...
Breaking Biology Technology:
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... -- Trends, opportunities and forecast in this market to ... AFIS, iris recognition, facial recognition, hand geometry, vein recognition, ... industry (government and law enforcement, commercial and retail, health ... and by region ( North America , ... , and the Rest of the World) ...
Breaking Biology News(10 mins):